What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.
Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.
An upcoming small biotech focused on IO targets with their novel platform approach
Some examples of potentially useful biomarker inclusion in early oncology trials
We offer 13 key highlights from day 2 of ASH18, including some surprises.
Update on BCMA, SLAMF7 and other targets in multiple myeloma
Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?